Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Atrium Therapeutics, Inc. Common Stock

RNA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of RNA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
RNA Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
RNA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RNA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in RNA holdings by institutional investors

Quarterly net insider trading by RNA's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Former government officials who have lobbied for RNA

5 former government officials from 3 congressional offices at 2 lobbying firms have lobbied for RNA, most recently Apr 17, 2026.

  • K. Michael Conaway
    Mark Williams House New Chief of Staff, Rep. Michael Conaway // Chief of Staff, Rep. Todd Rokita // Dep. Chief of Staff/Leg. Director, Rep. Sam Johnson. Formerly with K. Michael Conaway · FEROX STRATEGIES · Apr 17, 2026
  • Xavier Becerra
    Debra Dixon House New Chief of staff to Rep. Xavier Becerra, legislative director to Rep. Becerra, legislative counsel to Rep. Becerra, chief of staff, Office of Policy and Planning, U.S. Department of Education, Immigration Counsel, U.S. Department of Justice Formerly with Xavier Becerra · FEROX STRATEGIES · Apr 17, 2026
  • Cristina Antelo Senate New Legal Fellow, Senate Democratic Steering Committee. Formerly Legal Fellow, Senate Democratic Steering Committee. · FEROX STRATEGIES · Apr 17, 2026
  • Cathy McMorris Rodgers
    Michael Taggart House New Energy and Commerce Committee --Policy Director; Rep. Cathy McMorris Rodgers -- Legislative Director; Rep. Leonard Lance-- Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director Formerly with Cathy McMorris Rodgers · FEROX STRATEGIES · Apr 17, 2026
  • Charles Sydnor Congress New Rep. Wilson- legislative assistant/counsel; Senator Boozman- legislative assistant/counsel; Senator Burr- legislative assistant/counsel Formerly Wilson- legislative assistant · CASSIDY & ASSOCIATES, INC. · Sep 22, 2021

RNA Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

RNA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
RNA Income Statement
RNA Balance Sheet
RNA Cash Flow
U.S. Patents

New RNA patent grants

  • Patent Title: Compositions and methods of treating muscle dystrophy Jun. 09, 2026
  • Patent Title: Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping Jun. 09, 2026
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 20, 2026
  • Patent Title: Nucleic acid compositions and methods of multi-exon skipping Dec. 16, 2025
  • Patent Title: Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates Dec. 09, 2025
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 02, 2025
  • Patent Title: Compositions and methods of treating muscle dystrophy Sep. 30, 2025
  • Patent Title: Compositions comprising pln-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy Sep. 09, 2025
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jul. 22, 2025
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jul. 22, 2025
  • Patent Title: Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping Jul. 15, 2025
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jul. 08, 2025
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Apr. 01, 2025
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 25, 2025
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 03, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Oct. 01, 2024
  • Patent Title: Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping Aug. 27, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Aug. 27, 2024
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 20, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jul. 30, 2024
  • Patent Title: Una amidites and uses thereof Jun. 11, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jun. 04, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Feb. 27, 2024
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 16, 2024
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Dec. 05, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
  • Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
  • Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
  • Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
  • Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
  • Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to RNA from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
RNA News

Recent insights relating to RNA

CNBC Recommendations

Recent picks made for RNA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RNA

RNA Analyst Ratings

RNA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
RNA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $RNA stock a Buy, Sell, or Hold?

  • What is the price target for $RNA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

RNA Top Shareholders
Shareholder
Shares Held
RNA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $RNA stock?

  • Who owns the most shares of $RNA stock?

  • What funds own $RNA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

RNA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RNA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About RNA

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

  • Address San Diego, CA
  • Market Cap 140.1 million
  • Employees 391
  • Industrial Classification Pharmaceutical Preparations

Atrium Therapeutics, Inc. Common Stock (RNA) Historical Stock Prices

Atrium Therapeutics, Inc. Common Stock (RNA) closed at $8.19 on September 24, 2026. Over the past year its adjusted close ranged from $8.19 to $72.93. Daily prices go back to January 2, 2014, 1,858 trading days in all.

  • 1 month-41.50%
  • 3 months-35.92%
  • Year to date-88.65%
  • 1 year-81.05%
  • 3 years+30.00%
  • 5 years-65.04%
  • Max+61.86%
See every congressional and insider trade on the RNA price chart

Quiver Premium charts RNA's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 24, 2026 8.30 8.49 8.16 8.19 8.19 355,242
Sep 23, 2026 9.22 9.31 8.29 8.33 8.33 434,524
Sep 22, 2026 9.24 9.48 9.17 9.22 9.22 241,277
Sep 21, 2026 8.97 9.34 8.94 9.19 9.19 481,266
Sep 18, 2026 9.57 9.66 8.66 8.95 8.95 1,036,990
Sep 17, 2026 9.65 9.70 9.44 9.56 9.56 569,619
Sep 16, 2026 10.11 10.11 9.50 9.50 9.50 356,436
Sep 15, 2026 10.21 10.21 9.62 10.09 10.09 274,580
Sep 14, 2026 10.37 10.71 10.15 10.21 10.21 255,714
Sep 11, 2026 10.37 10.41 10.00 10.36 10.36 247,499
Sep 10, 2026 10.44 10.74 10.28 10.35 10.35 421,628
Sep 9, 2026 11.20 11.20 10.34 10.51 10.51 690,444
Sep 8, 2026 14.08 14.19 10.75 11.35 11.35 1,722,578
Sep 4, 2026 14.51 14.65 14.01 14.19 14.19 167,785
Sep 3, 2026 14.19 14.68 13.99 14.60 14.60 164,905
Sep 2, 2026 13.77 14.10 13.76 14.06 14.06 111,641
Sep 1, 2026 13.24 13.92 13.20 13.77 13.77 178,705
Aug 31, 2026 13.53 13.55 13.10 13.32 13.32 97,048
Aug 28, 2026 13.87 13.95 13.51 13.64 13.64 108,637
Aug 27, 2026 13.78 14.09 13.59 13.98 13.98 120,562
Aug 26, 2026 13.93 14.07 13.66 13.85 13.85 179,349
Aug 25, 2026 13.72 14.05 13.41 14.00 14.00 166,578
Aug 24, 2026 13.27 13.63 13.04 13.62 13.62 140,555
Aug 21, 2026 13.53 13.59 12.96 13.20 13.20 180,677
Aug 20, 2026 13.75 13.88 13.20 13.48 13.48 218,806
Aug 19, 2026 13.00 13.72 12.85 13.71 13.71 360,317
Aug 18, 2026 12.91 12.96 12.72 12.84 12.84 107,917
Aug 17, 2026 12.78 13.35 12.78 12.96 12.96 212,552
Aug 14, 2026 12.21 12.97 12.08 12.84 12.84 176,079
Aug 13, 2026 12.21 12.46 12.03 12.33 12.33 127,137
Aug 12, 2026 12.27 12.35 12.06 12.17 12.17 84,174
Aug 11, 2026 12.25 12.44 12.20 12.27 12.27 84,252
Aug 10, 2026 12.25 12.44 12.20 12.24 12.24 108,983
Aug 7, 2026 12.15 12.48 12.14 12.34 12.34 103,286
Aug 6, 2026 11.96 12.31 11.88 12.11 12.11 193,102
Aug 5, 2026 11.53 11.99 11.46 11.74 11.74 171,863
Aug 4, 2026 11.40 11.74 11.35 11.54 11.54 137,005
Aug 3, 2026 11.45 11.53 11.30 11.33 11.33 91,505
Jul 31, 2026 11.44 11.54 11.20 11.35 11.35 116,293
Jul 30, 2026 11.19 11.55 11.19 11.46 11.46 91,837
Jul 29, 2026 11.46 11.46 11.13 11.18 11.18 119,407
Jul 28, 2026 11.59 11.62 11.36 11.49 11.49 91,974
Jul 27, 2026 11.61 11.80 11.46 11.57 11.57 82,816
Jul 24, 2026 11.98 11.98 11.48 11.49 11.49 120,943
Jul 23, 2026 12.00 12.14 11.78 11.91 11.91 101,291
Jul 22, 2026 12.28 12.35 12.09 12.17 12.17 99,941
Jul 21, 2026 11.73 12.35 11.61 12.29 12.29 181,993
Jul 20, 2026 12.14 12.15 11.75 11.76 11.76 186,121
Jul 17, 2026 12.01 12.30 11.97 12.15 12.15 122,260
Jul 16, 2026 12.29 12.29 11.93 12.16 12.16 182,680
Jul 15, 2026 12.26 12.40 12.05 12.30 12.30 88,791
Jul 14, 2026 12.26 12.47 12.05 12.22 12.22 208,071
Jul 13, 2026 12.40 12.59 12.21 12.22 12.22 178,885
Jul 10, 2026 12.87 12.87 12.20 12.46 12.46 319,920
Jul 9, 2026 13.40 13.44 12.75 12.91 12.91 239,511
Jul 8, 2026 13.07 13.38 12.86 13.37 13.37 203,176
Jul 7, 2026 13.14 13.36 12.95 13.24 13.24 257,320
Jul 6, 2026 13.60 13.61 12.76 13.01 13.01 206,744
Jul 2, 2026 13.40 13.71 13.20 13.65 13.65 196,855
Jul 1, 2026 13.43 13.80 13.26 13.30 13.30 150,363
Jun 30, 2026 13.67 13.80 13.22 13.45 13.45 316,750
Jun 29, 2026 13.20 13.80 13.20 13.65 13.65 382,171
Jun 26, 2026 12.78 13.20 12.72 13.19 13.19 758,712
Jun 25, 2026 12.93 13.07 12.70 12.78 12.78 262,214
Jun 24, 2026 12.86 13.00 12.74 12.83 12.83 123,386
Jun 23, 2026 12.89 13.14 12.76 12.81 12.81 242,376
Jun 22, 2026 12.65 12.96 12.59 12.94 12.94 221,017
Jun 18, 2026 12.83 12.96 12.20 12.66 12.66 294,100
Jun 17, 2026 12.73 12.82 12.28 12.48 12.48 190,259
Jun 16, 2026 12.75 12.75 12.40 12.61 12.61 160,535
Jun 15, 2026 12.40 12.76 12.30 12.75 12.75 261,506
Jun 12, 2026 12.43 12.46 12.16 12.37 12.37 103,634
Jun 11, 2026 11.69 12.53 11.40 12.43 12.43 328,730
Jun 10, 2026 11.86 11.99 11.64 11.67 11.67 136,611
Jun 9, 2026 11.60 11.89 11.45 11.76 11.76 201,685
Jun 8, 2026 11.90 11.91 11.48 11.55 11.55 126,141
Jun 5, 2026 12.30 12.38 11.77 11.80 11.80 209,487
Jun 4, 2026 12.26 12.62 12.17 12.30 12.30 126,051
Jun 3, 2026 12.27 12.39 12.12 12.17 12.17 150,062
Jun 2, 2026 12.59 12.59 12.20 12.25 12.25 180,687
Jun 1, 2026 13.00 13.10 12.35 12.68 12.68 209,588
May 29, 2026 13.27 13.60 12.94 13.00 13.00 321,261
May 28, 2026 13.10 14.13 12.97 13.36 13.36 345,306
May 27, 2026 13.08 13.12 12.93 13.00 13.00 169,152
May 26, 2026 13.20 13.29 12.95 13.06 13.06 170,909
May 22, 2026 13.01 13.28 12.98 13.09 13.09 292,225
May 21, 2026 12.61 13.13 12.61 13.04 13.04 252,364
May 20, 2026 12.94 13.01 12.61 12.72 12.72 168,131
May 19, 2026 12.96 13.20 12.74 12.95 12.95 273,074
May 18, 2026 13.24 13.56 12.85 12.95 12.95 147,198
May 15, 2026 13.48 13.97 13.04 13.23 13.23 234,436
May 14, 2026 13.27 13.51 13.00 13.27 13.27 100,281
May 13, 2026 13.11 13.30 12.91 13.30 13.30 100,790
May 12, 2026 13.34 13.40 13.06 13.14 13.14 179,471
May 11, 2026 13.08 13.50 13.07 13.25 13.25 169,893
May 8, 2026 12.88 13.19 12.84 13.07 13.07 109,772
May 7, 2026 13.07 13.20 12.80 12.96 12.96 189,117
May 6, 2026 12.94 13.30 12.80 13.09 13.09 277,608
May 5, 2026 12.93 13.04 12.75 12.91 12.91 321,000
May 4, 2026 13.30 13.57 12.81 12.87 12.87 144,451
May 1, 2026 12.76 13.48 12.76 13.43 13.43 169,380
Apr 30, 2026 13.00 13.49 12.71 12.77 12.77 252,152
Apr 29, 2026 12.50 13.06 12.50 12.99 12.99 162,606
Apr 28, 2026 13.00 13.00 12.51 12.55 12.55 452,469
Apr 27, 2026 13.59 13.66 12.79 12.90 12.90 287,666
Apr 24, 2026 13.78 13.78 13.46 13.49 13.49 196,598
Apr 23, 2026 14.01 14.80 13.68 13.85 13.85 510,999
Apr 22, 2026 13.61 13.92 13.50 13.66 13.66 583,718
Apr 21, 2026 14.24 14.30 13.51 13.53 13.53 519,524
Apr 20, 2026 14.42 14.50 14.20 14.30 14.30 548,028
Apr 17, 2026 13.99 14.62 13.98 14.41 14.41 632,810
Apr 16, 2026 14.46 14.51 13.88 14.03 14.03 275,086
Apr 15, 2026 14.00 14.60 13.91 14.54 14.54 568,270
Apr 14, 2026 13.31 14.05 13.18 14.02 14.02 670,481
Apr 13, 2026 12.66 13.31 12.66 13.30 13.30 1,453,814
Apr 10, 2026 13.64 13.79 12.63 12.71 12.71 1,028,056
Apr 9, 2026 13.71 13.93 13.60 13.72 13.72 219,233
Apr 8, 2026 14.00 14.18 13.54 13.70 13.70 213,973
Apr 7, 2026 13.61 13.99 13.55 13.99 13.99 234,898
Apr 6, 2026 13.44 13.92 13.44 13.67 13.67 172,927
Apr 2, 2026 13.40 13.71 13.31 13.44 13.44 281,726
Apr 1, 2026 13.36 13.90 13.36 13.47 13.47 304,235
Mar 31, 2026 13.41 13.53 13.05 13.37 13.37 921,417
Mar 30, 2026 13.16 13.60 13.00 13.55 13.55 566,732
Mar 27, 2026 13.00 13.28 12.90 13.23 13.23 410,779
Mar 26, 2026 12.99 13.24 12.95 13.10 13.10 230,977
Mar 25, 2026 13.41 13.41 12.77 13.09 13.09 292,520
Mar 24, 2026 13.18 13.50 13.11 13.20 13.20 1,210,049
Mar 23, 2026 13.21 13.50 12.99 13.20 13.20 408,146
Mar 20, 2026 12.67 13.28 12.32 13.13 13.13 1,119,414
Mar 19, 2026 12.30 12.87 11.95 12.69 12.69 566,831
Mar 18, 2026 13.76 13.76 12.29 12.32 12.32 1,758,634
Mar 17, 2026 13.74 13.89 13.61 13.77 13.77 308,309
Mar 16, 2026 13.77 13.99 13.65 13.79 13.79 254,805
Mar 13, 2026 14.47 14.55 13.57 13.75 13.75 692,357
Mar 12, 2026 14.70 14.76 14.42 14.54 14.54 467,847
Mar 11, 2026 14.70 15.84 14.60 14.80 14.80 738,885
Mar 10, 2026 14.82 15.34 14.60 14.67 14.67 752,499
Mar 9, 2026 14.59 15.01 14.00 14.79 14.79 829,241
Mar 6, 2026 15.26 15.79 14.71 14.82 14.82 1,117,192
Mar 5, 2026 16.61 16.77 15.25 15.47 15.47 1,623,780
Mar 4, 2026 15.32 16.57 15.32 16.54 16.54 2,002,943
Mar 3, 2026 14.70 15.88 14.44 15.67 15.67 2,894,980
Mar 2, 2026 13.81 15.51 13.81 14.91 14.91 3,208,689
Feb 27, 2026 14.58 15.93 13.06 14.75 14.75 7,963,593
Feb 25, 2026 72.73 72.90 72.68 72.80 72.80 12,055,813
Feb 24, 2026 72.92 72.98 72.73 72.75 72.75 5,414,206
Feb 23, 2026 72.81 73.05 72.81 72.92 72.92 3,701,303
Feb 20, 2026 72.83 72.92 72.73 72.86 72.86 8,083,145
Feb 19, 2026 72.83 72.93 72.75 72.86 72.86 2,548,122
Feb 18, 2026 72.88 72.91 72.75 72.83 72.83 1,951,419
Feb 17, 2026 72.99 72.99 72.76 72.86 72.86 2,739,742
Feb 13, 2026 72.90 73.00 72.75 72.87 72.87 2,277,252
Feb 12, 2026 73.00 73.01 72.87 72.91 72.91 3,467,503
Feb 11, 2026 72.88 72.92 72.69 72.92 72.92 2,172,905
Feb 10, 2026 72.85 72.94 72.84 72.89 72.89 3,116,657
Feb 9, 2026 72.81 72.95 72.80 72.89 72.89 1,851,828
Feb 6, 2026 72.92 72.95 72.78 72.90 72.90 3,282,990
Feb 5, 2026 72.76 72.92 72.64 72.82 72.82 3,461,083
Feb 4, 2026 73.00 73.00 72.66 72.72 72.72 3,980,681
Feb 3, 2026 72.80 73.06 72.71 72.93 72.93 3,803,754
Feb 2, 2026 72.55 72.76 72.40 72.74 72.74 1,404,628
Jan 30, 2026 72.57 72.66 72.44 72.57 72.57 1,266,235
Jan 29, 2026 72.46 72.60 72.41 72.57 72.57 1,030,322
Jan 28, 2026 72.57 72.62 72.40 72.46 72.46 2,366,682
Jan 27, 2026 72.64 72.66 72.56 72.64 72.64 536,608
Jan 26, 2026 72.55 72.63 72.55 72.63 72.63 1,125,603
Jan 23, 2026 72.61 72.72 72.55 72.60 72.60 1,217,440
Jan 22, 2026 72.65 72.74 72.55 72.74 72.74 1,944,477
Jan 21, 2026 72.45 72.67 72.45 72.65 72.65 1,797,661
Jan 20, 2026 72.45 72.53 72.45 72.47 72.47 1,159,411
Jan 16, 2026 72.60 72.62 72.47 72.51 72.51 1,449,110
Jan 15, 2026 72.52 72.70 72.42 72.60 72.60 1,160,479
Jan 14, 2026 72.38 72.56 72.38 72.54 72.54 1,014,237
Jan 13, 2026 72.32 72.46 72.32 72.43 72.43 1,193,922
Jan 12, 2026 72.29 72.37 72.23 72.35 72.35 1,521,453
Jan 9, 2026 72.33 72.41 72.30 72.37 72.37 1,122,166
Jan 8, 2026 72.28 72.42 72.25 72.37 72.37 2,271,826
Jan 7, 2026 72.23 72.47 72.22 72.37 72.37 1,653,966
Jan 6, 2026 72.05 72.32 72.03 72.25 72.25 2,767,007
Jan 5, 2026 72.04 72.15 72.00 72.07 72.07 4,664,241
Jan 2, 2026 72.15 72.16 72.00 72.10 72.10 2,806,418
Dec 31, 2025 72.12 72.17 72.00 72.13 72.13 1,180,819
Dec 30, 2025 72.13 72.19 72.11 72.15 72.15 656,641
Dec 29, 2025 72.14 72.18 72.05 72.17 72.17 590,436
Dec 26, 2025 72.14 72.18 72.04 72.13 72.13 687,395
Dec 24, 2025 72.11 72.30 72.09 72.18 72.18 625,162
Dec 23, 2025 72.06 72.19 72.05 72.14 72.14 1,153,968
Dec 22, 2025 72.11 72.27 71.99 72.20 72.20 2,213,455
Dec 19, 2025 72.16 72.61 72.02 72.34 72.34 6,465,783
Dec 18, 2025 71.96 72.20 71.96 72.14 72.14 3,026,822
Dec 17, 2025 71.91 72.02 71.83 71.87 71.87 2,037,579
Dec 16, 2025 71.80 71.99 71.75 71.97 71.97 2,506,514
Dec 15, 2025 71.70 71.90 71.70 71.86 71.86 2,025,340
Dec 12, 2025 71.59 71.88 71.52 71.83 71.83 1,978,459
Dec 11, 2025 71.35 71.66 71.34 71.60 71.60 1,813,101
Dec 10, 2025 71.34 71.45 71.31 71.35 71.35 2,094,855
Dec 9, 2025 71.23 71.50 71.23 71.30 71.30 2,893,169
Dec 8, 2025 71.70 71.76 71.18 71.26 71.26 3,449,977
Dec 5, 2025 71.61 71.79 71.58 71.63 71.63 2,961,498
Dec 4, 2025 71.54 71.69 71.42 71.54 71.54 2,514,106
Dec 3, 2025 71.58 71.76 71.56 71.58 71.58 1,674,277
Dec 2, 2025 71.54 71.66 71.12 71.54 71.54 2,314,607
Dec 1, 2025 71.55 71.64 71.23 71.35 71.35 2,456,238
Nov 28, 2025 71.64 71.78 71.57 71.70 71.70 1,074,967
Nov 26, 2025 71.45 71.75 71.33 71.56 71.56 1,748,204
Nov 25, 2025 71.20 71.63 71.06 71.55 71.55 2,523,598
Nov 24, 2025 70.70 71.30 70.69 71.20 71.20 2,844,718
Nov 21, 2025 70.67 70.98 70.52 70.56 70.56 3,080,965
Nov 20, 2025 70.89 71.04 70.42 70.65 70.65 2,922,012
Nov 19, 2025 70.79 71.02 70.70 70.89 70.89 2,895,454
Nov 18, 2025 70.73 70.86 70.46 70.85 70.85 3,049,321
Nov 17, 2025 70.80 71.05 70.51 70.68 70.68 4,175,815
Nov 14, 2025 70.80 71.09 70.59 70.80 70.80 2,394,963
Nov 13, 2025 70.90 70.95 70.61 70.84 70.84 3,519,340
Nov 12, 2025 70.70 70.98 70.55 70.82 70.82 3,018,294
Nov 11, 2025 69.86 70.76 69.84 70.70 70.70 5,715,574
Nov 10, 2025 69.85 69.87 69.77 69.84 69.84 2,787,311
Nov 7, 2025 69.79 69.85 69.67 69.84 69.84 6,153,279
Nov 6, 2025 69.84 69.86 69.77 69.78 69.78 5,422,379
Nov 5, 2025 69.85 69.85 69.79 69.80 69.80 8,228,532
Nov 4, 2025 69.78 69.87 69.76 69.83 69.83 8,270,890
Nov 3, 2025 69.77 69.88 69.75 69.80 69.80 6,035,086
Oct 31, 2025 69.73 69.91 69.65 69.85 69.85 11,038,941
Oct 30, 2025 69.71 69.83 69.50 69.69 69.69 11,906,728
Oct 29, 2025 69.96 69.96 69.62 69.65 69.65 25,128,359
Oct 28, 2025 69.92 70.00 69.86 69.93 69.93 27,996,143
Oct 27, 2025 70.31 70.51 69.88 70.00 70.00 70,587,790
Oct 24, 2025 48.99 50.25 48.79 49.15 49.15 1,269,675
Oct 23, 2025 47.11 49.09 46.37 48.55 48.55 926,623
Oct 22, 2025 49.05 49.50 46.29 46.86 46.86 1,592,491
Oct 21, 2025 49.00 49.45 48.25 49.05 49.05 933,349
Oct 20, 2025 48.66 50.22 47.91 49.01 49.01 1,949,246
Oct 17, 2025 48.78 49.38 46.09 47.89 47.89 1,998,939
Oct 16, 2025 51.09 51.79 48.21 48.78 48.78 1,716,100
Oct 15, 2025 48.21 51.49 48.05 50.47 50.47 1,781,581
Oct 14, 2025 47.71 48.61 46.75 48.13 48.13 1,601,417
Oct 13, 2025 50.48 50.86 48.61 48.96 48.96 1,256,758
Oct 10, 2025 51.00 52.17 49.46 49.77 49.77 2,240,732
Oct 9, 2025 48.42 51.48 48.42 50.77 50.77 1,787,641
Oct 8, 2025 47.00 49.48 46.59 48.26 48.26 1,153,141
Oct 7, 2025 46.60 46.99 45.47 46.95 46.95 1,152,859
Oct 6, 2025 46.93 47.96 45.16 46.18 46.18 1,300,672
Oct 3, 2025 44.63 47.30 44.28 47.00 47.00 1,461,488
Oct 2, 2025 43.24 44.19 43.15 44.18 44.18 1,272,031
Oct 1, 2025 44.23 45.00 42.84 43.00 43.00 1,537,685
Sep 30, 2025 42.66 43.69 42.26 43.57 43.57 2,579,721
Sep 29, 2025 42.95 43.59 38.94 42.63 42.63 2,983,339
Sep 26, 2025 41.40 43.12 40.70 42.95 42.95 3,008,566
Sep 25, 2025 43.32 43.32 40.70 40.84 40.84 1,567,903
Sep 24, 2025 42.05 44.50 41.84 43.21 43.21 1,606,020

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Atrium Therapeutics, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at RNA, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation